Earnings Beat on Revenue, Pressure on Profitability

U.S. Physical Therapy (USPH) reported second quarter 2026 results that combined higher revenue with weaker profitability. Revenue slightly surpassed analyst expectations, while earnings per share came in below forecasts and declined compared to the prior year.

For the quarter ended June 30, 2026, revenue was reported at $214.06 million, compared with $197.34 million a year earlier. Net income was $9.9 million versus $12.39 million in the same period last year.

Basic and diluted earnings per share from continuing operations were $0.25, compared with $0.58 a year ago. The company also highlighted that patient visits and net rate per patient visit were slightly ahead of analyst expectations, while net revenue per patient and other revenue trailed forecasts but still showed positive year over year progress.

Over the first six months of 2026, U.S. Physical Therapy reported revenue of $412.34 million, compared with $381.13 million a year earlier. Net income for the period was $14.94 million, compared with $22.29 million in the prior year period.

Basic and diluted earnings per share from continuing operations for the six month period were $0.13, compared with $1.38 a year ago. This combination of top line growth and lower earnings gives investors a mixed picture of current operating performance.

Following these results and the dividend affirmation on 5 August 2026, U.S. Physical Therapy's share price has shown stronger short term momentum, with a 30 day share price return of 13.9% and a 90 day return of 35.01%. However, the 1 year total shareholder return has declined 6.4%, suggesting recent optimism is still working against a weaker longer term record.

If you are weighing U.S. Physical Therapy against other opportunities in healthcare related growth, it could be a good moment to broaden your watchlist with 42 healthcare AI stocks

U.S. Physical Therapy now trades at a visible discount to both analyst targets and some intrinsic value estimates, even after the recent share price rebound. Is that discount a genuine opportunity or a fair reflection of the profit pressure on display?

Most Popular Narrative: 14.5% Undervalued

Compared with the latest close at $80.05, the most widely followed narrative for U.S. Physical Therapy points to a fair value of $93.67, using a detailed long term earnings model.

Strategic cost efficiency initiatives, such as AI-driven clinical documentation, semi-virtualized front desk operations, and recruitment/retention technology, are beginning to materially lower operating and labor costs per visit, directly improving net margins and earnings potential.

Want to see what this efficiency story really assumes for U.S. Physical Therapy? The narrative leans heavily on rising margins and faster earnings growth, paired with a future valuation multiple that looks very different from today.

Result: Fair Value of $93.67 (UNDERVALUED)

However, U.S. Physical Therapy still faces meaningful risks, including ongoing reimbursement pressure and higher labor costs, which could undermine the margin recovery that this valuation narrative assumes.

Another View on U.S. Physical Therapy's Valuation

The most followed narrative for U.S. Physical Therapy leans on future earnings to claim the stock looks 14.5% undervalued at $80.05 versus a $93.67 fair value. Our fair ratio points to a different story. At a P/S of 1.5x versus a fair ratio of 0.7x and an industry average of 1.4x, the current price could also reflect valuation risk rather than a pure discount. Which lens do you think fits the business better?

Next Steps

Given this mix of pressure and potential around U.S. Physical Therapy, it helps to move quickly and weigh the data against your own expectations. To see both sides of the debate in one place, review the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond U.S. Physical Therapy?

If U.S. Physical Therapy caught your attention, keep that momentum going. Fresh ideas often appear when you compare this stock with others built on different strengths.

• Target stability and income by reviewing companies with reliable payouts and defensible cash flows through the 8 dividend fortresses.
• Hunt for potential mispriced opportunities by scanning the market for quality stocks trading below their estimated worth using the 49 high quality undervalued stocks.
• Prioritise resilience by focusing on businesses with strong finances and lower perceived risk through the 78 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.